Gut bacteria may predict whether melanoma immunotherapy works, review finds

If you or someone you love is facing melanoma and weighing immunotherapy, you have probably already wondered why the same drug helps one patient and does almost nothing for another. A new systematic review pulling together 25 separate studies suggests part of the answer may be sitting in the gut. Patients whose intestines carry more of certain short-chain-fatty-acid-producing bacteria tend to respond better to immune checkpoint inhibitors, the class of drugs that includes anti-PD-1 and anti-CTLA-4 therapies.

Key takeaways:

• A review of 25 studies (out of 380 screened) found that gut bacteria linked to short-chain fatty acid (SCFA) production, especially Faecalibacterium prausnitzii and Akkermansia muciniphila, were repeatedly tied to better responses to melanoma immunotherapy, while dysbiosis (an imbalanced gut microbial community) and certain fungal overgrowth tracked with worse outcomes.
• No single bacterial species reliably predicted response across every study population, so a gut microbiome test is not ready to guide treatment decisions.
• The underlying evidence is entirely observational: 17 of 25 studies carried a moderate risk of bias and 8 carried a serious risk, mostly due to small, single-center designs.
• Researchers say large, standardized, multicenter studies are still needed before microbiome results could ever factor into a real treatment plan.

Gut Bacteria Track Response to Checkpoint Inhibitors

Higher abundance of short-chain-fatty-acid-producing bacteria, most consistently Faecalibacterium prausnitzii and Akkermansia muciniphila, was repeatedly associated with better responses to immune checkpoint inhibitors (ICIs) in melanoma patients, according to a systematic review published in Cureus. Immune checkpoint inhibitors are a class of antibody drugs, including anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents, that block signals tumors use to switch off the immune system's T cells (a type of white blood cell that can attack cancer). The reviewer, Keemaya G. Joglekar, screened 380 records from PubMed and pulled 25 original human studies published between 2015 and 2025 that measured gut microbiome composition directly against clinical response to these drugs. Across those studies, enrichment of pathogenic bacteria and fungi, a state called dysbiosis, was consistently linked to reduced treatment efficacy and worse survival.

Why Melanoma Patients on Immunotherapy Should Care

Immune checkpoint inhibitors have transformed outcomes for advanced melanoma, one of the most aggressive skin cancers, but only a subset of patients achieve durable responses, and doctors still lack a reliable way to predict who that will be beforehand. That gap matters practically: patients who will not respond to a given ICI regimen currently have no early warning and may spend months on a drug that will not work while the cancer progresses. The review found that microbiome-derived metabolites appear to influence antitumor immunity by affecting dendritic cell function (the immune cells that "present" tumor targets to T cells) and T-cell activation, giving a plausible biological reason why gut bacteria could matter for a therapy that has nothing to do with digestion. Beyond effectiveness, the review also flagged a safety angle: certain bacterial patterns, including higher Bacteroides intestinalis and a Bacteroides dorei-dominant gut community, were linked to a roughly sevenfold higher risk of severe immune-related side effects in some cohorts, meaning the microbiome connection cuts both ways, toward both benefit and harm.

How the Review Was Built

This was a systematic review, not a new experiment. Joglekar searched PubMed for studies combining melanoma, gut microbiome, and immune checkpoint inhibitor terms, screened 380 records after removing one duplicate, and assessed 68 full-text articles before settling on 25 that met the criteria: original, English-language, peer-reviewed human research published between 2015 and 2025 that measured gut microbiome composition directly against ICI response. Studies using fecal transplants, probiotic trials, or animal models were excluded, keeping the focus on naturally occurring gut bacteria in real patients. Sample sizes across the 25 studies ranged from 23 to 680 participants. Because the studies used different sequencing methods, outcome definitions, and analysis pipelines, the review pooled findings qualitatively rather than running a formal meta-analysis, and it applied a standard bias-assessment tool (ROBINS-I) to grade each study's reliability.

What This Means for Someone Managing Melanoma Right Now

Nothing in this review is a green light to start supplementing with probiotics, high-fiber diets, or any other intervention aimed at these specific bacteria before or during immunotherapy. The review explicitly excluded probiotic and dietary intervention trials, so it cannot tell you whether changing your gut bacteria on purpose would improve your odds. What it does support is a conversation worth having with an oncologist: gut microbiome research is an active area in melanoma care, and some patients are already being enrolled in microbiome-focused clinical trials at academic cancer centers. If you are currently on or considering an immune checkpoint inhibitor, the practical takeaway is patience rather than a home test kit. No microbiome-based test has been validated for clinical use, and the review found that even a well-known "beneficial" species like F. prausnitzii predicted non-response in one cohort while predicting better response in others, underscoring that context and strain-level differences matter more than a single bacterial name.

The Evidence Is Still Observational and Inconsistent

Every one of the 25 included studies was observational, meaning the studies observed existing patients rather than randomly assigning them to different microbiome states, which cannot establish that the bacteria caused the treatment response rather than simply correlating with it. The review's own bias assessment rated 17 of the 25 studies as moderate risk and 8 as serious risk, driven mainly by small, single-center patient groups. Findings were also inconsistent at the individual species level. Higher microbial diversity was tied to better responses in some studies but showed no difference at all in a confounder-adjusted analysis of 68 differentially abundant taxa. Diet, antibiotic use, geography, and host genetics all appeared to influence results across studies, and the review notes that publication bias, meaning unpublished negative studies going unrecorded, cannot be ruled out.

What Comes Next

The review's authors call for large, prospective, multicenter studies that combine microbiome sequencing with metabolomic profiling (measuring the small molecules bacteria actually produce) and standardized definitions of treatment response, arguing that this kind of coordinated, multi-omic approach is what would be needed before microbiome testing could move from a research finding into real clinical decision-making. One study included in the review offered an early hint of causality: giving a specific F. prausnitzii bacterial strain to antibiotic-treated mice restored their response to checkpoint blockade, a result the review's author describes as complementing the human observational data rather than confirming it. No timeline for clinical translation was given.

Common Questions

Can I test my gut microbiome to predict how I'll respond to immunotherapy? Not yet. No microbiome-based test has been validated for clinical use in melanoma immunotherapy, and the review found that specific bacterial signals were inconsistent across different patient populations.

Should I take a probiotic before starting immune checkpoint inhibitor treatment? This review did not test that question. Probiotic and dietary intervention trials were deliberately excluded from the analysis, so there is no evidence here that supplementing with these bacteria improves or worsens treatment outcomes, and unsupervised changes could carry unknown risks alongside cancer treatment.

Does having "good" gut bacteria guarantee immunotherapy will work? No. Even Faecalibacterium prausnitzii, one of the bacteria most consistently linked to better outcomes, predicted worse outcomes in at least one study cohort, showing that microbiome effects can depend on the specific patient population and bacterial strain involved.

Are these findings specific to melanoma, or do they apply to other cancers treated with immunotherapy? This review focused specifically on melanoma patients, though the broader idea that gut bacteria influence immune checkpoint inhibitor response has also been studied in other cancer types; those studies were outside this review's scope.

References

Keemaya G Joglekar (2026). Gut Microbiome Composition and Response to Immune Checkpoint Inhibitors in Melanoma: A Systematic Review. Cureus. https://doi.org/10.7759/cureus.113248